Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease
K Suresh Babu, Jaymin B Morjaria

Abstract

The recent Global Initiative for Chronic Obstructive Lung Disease (GOLD) chronic obstructive pulmonary disease (COPD) guidelines consider symptoms and exacerbation history in addition to the degree of airflow obstruction for classifying patients. The improvement of symptoms is principally provided by bronchodilators, using β2 agonists and antimuscarinic agents. Aclidinium bromide is a novel long-acting antimuscarinic agent licensed for use in patients with COPD. Novel fixed-dose combinations that are either licensed or in their late phase of development include vilanterol/umeclidinium, indacaterol/glycopyrronium, olodaterol/tiotropium and formoterol/aclidinium. Fixed-dose combinations of aclidinium/formoterol have been evaluated in COPD patients and evidence suggests that this is efficacious, safe, has a quick onset of action and is well tolerated. This review provides a clinico-pharmacological profile of this compound.

References

Feb 7, 2003·The European Respiratory Journal·F Di MarcoS Centanni
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Don D SinNick R Anthonisen
Nov 6, 2003·JAMA : the Journal of the American Medical Association·S F Paul ManDon D Sin
Jun 29, 2004·The European Respiratory Journal·D E O'DonnellH Magnussen
Jan 3, 2006·The European Respiratory Journal·K R ChapmanR Beasley
Dec 18, 2007·Respiratory Medicine·Federico LavoriniGraham K Crompton
Aug 30, 2008·Thorax·J Bourbeau, S J Bartlett
Jan 1, 2008·International Journal of Chronic Obstructive Pulmonary Disease·Andrea RossiMario Cazzola
May 20, 2009·Respiration; International Review of Thoracic Diseases·S P NewmanG de Miquel
May 30, 2009·The Journal of Pharmacology and Experimental Therapeutics·Paola CasarosaMichael Pieper
Aug 28, 2009·The Journal of Pharmacology and Experimental Therapeutics·Amadeu GavaldàJorge Beleta
Jan 15, 2011·British Journal of Pharmacology·Mario CazzolaMaria Gabriella Matera
Mar 4, 2011·Respiratory Medicine·Andrea S MelaniUNKNOWN Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri
Mar 25, 2011·The New England Journal of Medicine·Claus VogelmeierUNKNOWN POET-COPD Investigators
Apr 15, 2011·Respiratory Medicine·F LavoriniUNKNOWN Aerosol Drug Management Improvement Team
Apr 23, 2011·Therapeutic Advances in Respiratory Disease·Claus Vogelmeier, Donald Banerji
Oct 18, 2011·International Journal of Chronic Obstructive Pulmonary Disease·Michael W Sims, Reynold A Panettieri
Feb 22, 2012·International Journal of Clinical Practice·H Chrystyn, C Niederlaender
Mar 24, 2012·The European Respiratory Journal·Paul W JonesEsther Garcia Gil
May 23, 2012·Pharmacological Reviews·Mario CazzolaM Gabriella Matera
Aug 25, 2012·Expert Opinion on Investigational Drugs·Mario CazzolaMaria Gabriella Matera
Feb 19, 2013·COPD·Nadia N HanselUNKNOWN COPDGene Investigators
Mar 12, 2013·Expert Opinion on Pharmacotherapy·Mario CazzolaMaria Gabriella Matera
May 7, 2013·Respiratory Medicine·Mika J MäkeläKjell Larsson
May 9, 2013·Respiratory Research·Donald P Tashkin, Gary T Ferguson
Jun 12, 2013·Expert Opinion on Drug Delivery·Job van der PalenEsther Garcia Gil
Jul 23, 2013·Drug Discovery Today·A PrakashJ B Morjaria
Aug 29, 2013·ISRN Allergy·Federico Lavorini
Oct 2, 2013·The European Respiratory Journal·Mario CazzolaLuis Puente-Maestu
Oct 8, 2013·Respiratory Research·Shannon CopePaul Jones
Oct 22, 2013·Drug Discovery Today·Abhalaxmi Singh, Sanjeeb K Sahoo

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Clinical Trials Mentioned

NCT00706914
NCT01572792
NCT01437540

Software Mentioned

ACLIFORM
AUGMENT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.